CFRA upgrades GlaxoSmithKline stock to Buy on strong Q3 results
PositiveFinancial Markets

CFRA has upgraded GlaxoSmithKline's stock to a 'Buy' rating following strong third-quarter results. This upgrade reflects confidence in the company's performance and potential for growth, which is significant for investors looking for promising opportunities in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System






